Anticonvulsants

Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Pharmaceutical, Health, Chemical compounds, Anticonvulsants, GABAA receptor positive allosteric modulators, Ketones, Pregnanes, Sterols, Spacecraft, Ganaxolone, Spaceflight, Seizure, Maa, Orion, Ganaxolone, Marinus Pharmaceuticals, Orion Corporation, GANAXOLONE, MARINUS PHARMACEUTICALS, ORION CORPORATION

This collaboration not only serves as an important step in our global development strategy for ganaxolone, it also represents the confidence Orion has in its potential.

Key Points: 
  • This collaboration not only serves as an important step in our global development strategy for ganaxolone, it also represents the confidence Orion has in its potential.
  • Satu Ahomki, Senior Vice President, Commercial Operations of Orion Corporation said, We are pleased to be the partner of choice for Marinus in Europe.
  • What we have seen so far with ganaxolone is encouraging and signifies an ongoing commitment to the rare epilepsy communities.
  • Marinus expects to file a European marketing authorization application (MAA) for ganaxolone for the treatment of seizures associated with CDD by the end of Q3 2021.

Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, FDA, Pharmaceutical, Health, Chemical compounds, Anticonvulsants, GABAA receptor positive allosteric modulators, Orphan drugs, Ganaxolone, Pregnanes, Sedatives, Health care, Health, CDKL5 Deficiency Disorder, Ganaxolone, Marinus Pharmaceuticals, CDKL5 DEFICIENCY DISORDER, GANAXOLONE, MARINUS PHARMACEUTICALS

We look forward to working with the FDA in their review process and remain focused on preparing for the anticipated U.S. launch.

Key Points: 
  • We look forward to working with the FDA in their review process and remain focused on preparing for the anticipated U.S. launch.
  • Ganaxolone was generally well-tolerated with a safety profile consistent with previous clinical trials, with the most frequent adverse event being somnolence.
  • Marinus received Rare Pediatric Disease (RPD) Designation from the FDA for ganaxolone for the treatment of seizures associated with CDD in July 2020.
  • Further details are available in Marinus press release distributed August 3, 2021 (Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone).

Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Mental health, Health, Pharmaceutical, Managed care, GABAA receptor positive allosteric modulators, Psychoactive drugs, Anticonvulsants, Chemical compounds, Health sciences, Ketones, Pregnanes, Sterols, CDKL5 deficiency disorder, Ganaxolone, CDKL5, Allosteric modulator

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.

Key Points: 
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder last year and is conducting a Phase 2 trial in tuberous sclerosis complex and a Phase 3 trial in refractory status epilepticus.

Peels™ Debuts The Purest And Safest CBD On The Planet Made From Orange Peels, Guarantees Zero THC

Retrieved on: 
Tuesday, August 3, 2021
Drugs, Cannabinoids, Natural phenols, Resorcinols, Analgesics, Anticonvulsants, Cannabidiol, CBD

With both awards and certifications from Clean Label Project , Peels CBD Oil is the purest and safest CBD product on the market.

Key Points: 
  • With both awards and certifications from Clean Label Project , Peels CBD Oil is the purest and safest CBD product on the market.
  • "We're extremely proud of our CBD Oil and we know Peels is going to revolutionize the way people view and use CBD," continued Hetherington.
  • Peels offers the purest, safest CBD on the planet made from orange peels offering the highest quality, lowest risk cannabinoid product on the market.
  • Headquartered in Los Angeles, Peels is a data and science-driven CBD companydelivering better-for-you CBD wellness products.

Eisai's Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures

Retrieved on: 
Monday, August 2, 2021
Anticonvulsants, Clinical medicine, Nitriles, Perampanel, Pyridines, Eisai, Medicine, Health, Epilepsy, Seizure, Generalized epilepsy, Syndromes

Fycompa has already been approved in China as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older.

Key Points: 
  • Fycompa has already been approved in China as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older.
  • Through this approval, Fycompa is now available in China as a monotherapy and an adjunctive treatment for partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older.
  • Fycompa is a first-in-class AED and a once-daily tablet discovered at Eisai's Tsukuba Research Laboratories.
  • Eisai seeks to address the diverse needs of, as well as increase the benefits provided to, patients with epilepsy and their families.

Allied Corp Completes Commercial CBD Shipments From Colombia Into Australia

Retrieved on: 
Thursday, July 29, 2021
Drugs, Cannabinoids, Analgesics, Anticonvulsants, Cannabidiol, Resorcinols, CBD

("Allied" or the Company) (OTCQB: ALID) an international medical company focused on creating and providing health solutions to address todays medical mental health issues is pleased to announce that it has completed its commercial shipments of cannabidiol (CBD) isolate from Colombia to Australia.

Key Points: 
  • ("Allied" or the Company) (OTCQB: ALID) an international medical company focused on creating and providing health solutions to address todays medical mental health issues is pleased to announce that it has completed its commercial shipments of cannabidiol (CBD) isolate from Colombia to Australia.
  • Allied has demonstrated its supply chain of producing in Colombia and exporting wholesale CBD products into international markets.
  • This shipment was produced from seed in Colombia at Allieds commercial production site, approved for export by the Colombian ministries of Justice, Health and Agriculture and then transported to Australia.
  • Allied has now shipped CBD to Peru, Australia, Europe and the United States.

CBD Global Sciences Management Cease Trade Order (MCTO) Revoked by the Alberta Securities Commission

Retrieved on: 
Tuesday, July 27, 2021
Drugs, Cannabinoids, Analgesics, Anticonvulsants, Cannabidiol, Resorcinols, CBD, Hemp

Denver, Colorado, July 27, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- CBD Global Sciences, Inc. (OTC: CBDNF) (CSE: CBDN) (Frankfurt:GS3), (CBD Global or the Company), acknowledges the Cease Trade Order (CTO) issued by the Alberta Securities Commission on 7/23/21.

Key Points: 
  • Denver, Colorado, July 27, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- CBD Global Sciences, Inc. (OTC: CBDNF) (CSE: CBDN) (Frankfurt:GS3), (CBD Global or the Company), acknowledges the Cease Trade Order (CTO) issued by the Alberta Securities Commission on 7/23/21.
  • Brad Wyatt, CEO of CBD Global Sciences, shared, This action to seek bankruptcy protection was complicated process but not insurmountable.
  • ABOUT CBD GLOBAL SCIENCES INC.
    CBD Global Sciences, Inc., is a hemp-based CBD producer and branding investment vehicle which currently owns two brands, branded under the name Aethics ( www.aethics.com ) and CANNAOIL ( www.cannaoilshop.com ), which include CBD Oil tinctures (liquid products), CBD capsules, CBD topicals, Hydration products and Confectionary products.
  • CBD Global Sciences hemp-derived CBD extracts are sold through select distributors, brick and mortar retailers, and online.

CBD Product Sales Could Reach Nearly $17 Billion Dollars In The U.S. Alone By 2025

Retrieved on: 
Tuesday, July 27, 2021
Drugs, Anticonvulsants, Cannabidiol, Cannabinoids, Convenience store

A report from Statista added that In the United States, cannabidiol products generated sales of roughly five billion U.S. dollars in 2020.

Key Points: 
  • A report from Statista added that In the United States, cannabidiol products generated sales of roughly five billion U.S. dollars in 2020.
  • By 2025, CBD product salesare predicted to reach nearly 17 billion U.S. dollars in the United States.
  • With estimated sales of 730 million U.S. dollars, the state of California was the country's leading market for CBD products.
  • In American convenience stores, vitamins were the leading CBD segmentin terms of sales, generating over 20 million U.S. dollars in 2020.

CBD Product Sales Could Reach Nearly $17 Billion Dollars In The U.S. Alone By 2025

Retrieved on: 
Tuesday, July 27, 2021
Drugs, Anticonvulsants, Cannabidiol, Cannabinoids, Convenience store

A report from Statista added that In the United States, cannabidiol products generated sales of roughly five billion U.S. dollars in 2020.

Key Points: 
  • A report from Statista added that In the United States, cannabidiol products generated sales of roughly five billion U.S. dollars in 2020.
  • By 2025, CBD product salesare predicted to reach nearly 17 billion U.S. dollars in the United States.
  • With estimated sales of 730 million U.S. dollars, the state of California was the country's leading market for CBD products.
  • In American convenience stores, vitamins were the leading CBD segmentin terms of sales, generating over 20 million U.S. dollars in 2020.

CV Sciences, Inc. Receives NutraIngredients-USA 2021 Product of the Year: Immune Support Award

Retrieved on: 
Tuesday, July 27, 2021
Drugs, Medical specialties, Health care, Immunology, Anticonvulsants, Cannabidiol, Cannabinoids, Resorcinols, Hemp, Immunity

SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the Company, CV Sciences, our, us or we), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today that it received NutraIngredients-USA s 2021 Product of the Year: Immune Support Award for its CV Defense product.

Key Points: 
  • SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the Company, CV Sciences, our, us or we), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today that it received NutraIngredients-USA s 2021 Product of the Year: Immune Support Award for its CV Defense product.
  • The active ingredients in CV Defense are backed by hundreds of scientific studies for daily support of barrier immunity, innate immunity, and adaptive immunity.
  • CV Defense by CV Sciences stood out in a crowded category, said Stephen Daniells, PhD, Editor-in-Chief of NutraIngredients-USA.
  • This award also validates our strategic decision to expand our product portfolio beyond the hemp-derived CBD category that we pioneered.